Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line CLL/SLL trial of venetoclax + obinutuzumab versus venetoclax + pirtobrutinib, including MRD-guided treatment duration
MOH_2025-12-30_015574Phase 3Recruiting
- Sponsor
- University of Cologne
- Start
- Nov 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax, obinutuzumab and pirtobrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by University of Cologne. Primary endpoint: Progression-free survival. Started Nov 2025; status: recruiting.
02
Drugs
venetoclaxobinutuzumabpirtobrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2025-12-30_015574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-12-30_015574.